Welcome to our dedicated page for MDB Capital Holdings LLC-A news (Ticker: MDBH), a resource for investors and traders seeking the latest updates and insights on MDB Capital Holdings LLC-A stock.
MDB Capital Holdings, LLC reports developments as a public venture platform and investment holding company focused on launching and supporting disruptive technology companies. Its news commonly covers shareholder updates, operating results, portfolio-company positions, capital-market services and the activity of subsidiaries that combine broker-dealer, intellectual property and technology-development functions.
Company updates also feature PatentVest, MDB’s intellectual property intelligence, strategy and legal-services business. Recurring PatentVest releases discuss IP landscape reports, patent strategy, legal insights, biotechnology and medical-technology collaborations, and equity-linked service engagements that connect patent research, due diligence and venture formation.
PatentVest released a Pulse report (May 8, 2026) mapping the emerging triple-agonist obesity race and an intensifying patent battle shaping the post-GLP-1 market.
Key points: identification of 27 global triple-agonist programs, Eli Lilly’s retatrutide cited for near‑bariatric efficacy, rising importance of receptor‑ratio engineering, delivery platforms, formulation control, and latent IP holdings from multiple firms that could reshape future competition.
PatentVest released a April 29, 2026 report titled “The Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery.” Retatrutide achieved 28.7% mean weight loss, described as the first non-surgical therapy matching bariatric outcomes. The report maps the pipeline, deal activity, and IP structure, noting multiple industry entrants (Novo Nordisk, Pfizer via acquisition, Hanmi, Innovent, Hengrui) and that Sanofi holds the largest IP position with 27 programs. PatentVest warns the trial result may not hold in real-world use and highlights IP control and access as the next battleground.
MDB Capital Holdings (NASDAQ: MDBH) provided a 2025 full-year update and shareholder letter on March 31, 2026, detailing asset positions, cash, expenses, and strategic spin-outs.
Key points: an EXOZ stake valued at ~$30 million, Paulex seed funding of $19 million, year-end cash of ~$22.3 million, annual fixed operating expenses of ~$10 million, and net cash used of ~$5.7 million.
PatentVest (MDBH) released a Pulse report, “The Amylin Renaissance,” on March 31, 2026, detailing a rapid commercialization shift in amylin-based obesity therapies.
The report documents nearly 40 amylin receptor agonist programs, more than $19 billion in deal value committed over the past 18 months, clinical data showing up to 20%+ weight loss, an approaching FDA decision for a GLP-1/amylin combo, and growing oral small-molecule efforts. It emphasizes patent strategy as a decisive competitive factor.
PatentVest (NYSE:MDBH) added a new IP Legal Insights article on March 30, 2026, addressing patenting strategies for AI-assisted inventions. The piece, by Sarah Cork, Ph.D., Senior Patent Attorney, covers Section 101 eligibility, inventorship issues, claim drafting, and recent USPTO guidance shaping AI patent evaluation.
The article emphasizes demonstrating technological improvements, practical applications, and clear human contribution when seeking protection for AI-driven innovations.
PatentVest (MDBH) announced a strategic engagement with Life Seal Vascular on March 30, 2026, accepting equity as partial consideration for IP intelligence and legal services. The deal pairs PatentVest's proprietary IP platform with Life Seal Vascular's vascular device technology and signals a long-term commercial and strategic alignment.
The partnership aims to map competitive patent landscapes, identify patenting opportunities and risks, and inform R&D, licensing, and commercialization decisions for Life Seal Vascular.
MDB Capital Holdings (NASDAQ: MDBH) will host a Zoom webinar on Tuesday, March 31, 2026 at 4:30 p.m. ET to discuss its fourth quarter and full year 2025 results.
Christopher Marlett, CEO and Co-Founder, will lead the call; a press release with results will be issued prior to the webinar. Investors can pre-register for the Zoom webinar or access the live webcast via MDB’s investor relations site at https://investors.mdb.com/.
PatentVest (MDBH) announced on March 11, 2026 the completion of a strategic intellectual property engagement with Porosome Therapeutics to evaluate and strengthen its IP portfolio for secretion-restoration therapeutics.
PatentVest delivered an IP portfolio audit, global patent landscape analyses, competitive benchmarking, and partner assessment, and found Porosome Therapeutics has a distinct position in structural porosome reconstitution. Porosome plans additional filings covering organoid models, novel peptides, and small-molecule innovations to expand its IP estate.
PatentVest (Nasdaq: MDBH) released a PatentVest Pulse report, “The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron,” analyzing 1,200+ patent documents across 50 programs to assess patent depth and long-term exclusivity.
Key findings: clinical efficacy converging at 12–16% weight loss, $71 billion injectable GLP-1 market, $47 billion in GLP-1 deal value since 2023, and looming patent cliffs for semaglutide (2031) and tirzepatide (2036).
MDB Capital Holdings (NASDAQ: MDBH) announced board transitions effective February 1, 2026. Jeb Terry, Sr. was appointed to the board; Susanne L. Meline concluded her board service and will remain a shareholder and advocate. The company cited Terry's two decades in microcap life sciences investing and his leadership at Aberdeen Investment Management (2010–2025).
MDB said these changes support its strategy to scale a public venture platform that launches and finances early-stage, category-leading companies.